- Report
- February 2025
- 200 Pages
Global
From €4195EUR$4,490USD£3,549GBP
- Report
- March 2025
- 200 Pages
Global
From €4195EUR$4,490USD£3,549GBP
- Drug Pipelines
- August 2024
- 180 Pages
Global
From €2336EUR$2,500USD£1,976GBP
- Report
- July 2021
- 50 Pages
China
From €2429EUR$2,600USD£2,055GBP
- Report
- August 2019
- 30 Pages
China
From €2055EUR$2,200USD£1,739GBP
- Report
- June 2023
- 113 Pages
Global
From €4157EUR$4,450USD£3,517GBP
- Report
- March 2024
- 134 Pages
Global
From €7427EUR$7,950USD£6,283GBP
- Report
- February 2024
- 150 Pages
Global
From €7427EUR$7,950USD£6,283GBP
- Report
- August 2022
- 30 Pages
Global
From €2569EUR$2,750USD£2,173GBP
- Report
- August 2024
- 80 Pages
Japan
From €3270EUR$3,500USD£2,766GBP
- Report
- October 2023
- 189 Pages
Global
From €4204EUR$4,500USD£3,556GBP
- Report
- February 2024
- 88 Pages
Global
From €3500EUR$4,013USD£3,065GBP
Mycophenolate is a drug used in the treatment of hematological diseases, such as aplastic anemia, myelodysplastic syndrome, and certain types of leukemia. It is an immunosuppressant, meaning it suppresses the body's immune system, which can help reduce the risk of rejection of transplanted organs. Mycophenolate is also used to treat autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis.
Mycophenolate is available in both oral and intravenous forms, and is typically prescribed in combination with other drugs. Common side effects include nausea, vomiting, diarrhea, and abdominal pain. It is important to note that mycophenolate can cause serious side effects, including an increased risk of infection and an increased risk of certain types of cancer.
The mycophenolate market is highly competitive, with many companies offering generic and branded versions of the drug. Some of the major players in the market include Novartis, Pfizer, Merck, and Teva Pharmaceuticals. Show Less Read more